Search

Coating seeds in taste-averting chemical defenses (e.g., capsaicin from Capsicum spp.) can reduce rodent seed predation, and thus might promote plant establishment and forest regeneration. However, the efficacy of such seed coatings remains unknown for many woody plant species, and seed coatings have not been evaluated across different habitats where forest managers might seek to promote forest regeneration. We used two complementary seed-removal experiments in closed-canopy forests (Michigan) and an old field undergoing reforestation (New York) to examine whether coating seeds of four native tree species (Acer rubrum, Fagus grandifolia, Pinus banksiana, and Pinus resinosa) with chili powder reduces seed removal by rodents. In all species and habitats, control seeds were removed more than seeds treated with capsaicin (94% more in the closed-canopy forest, 17% more in the old field). Seed coatings containing capsaicin may provide a generally effective tool to support native tree recruitment and promote restoration success. [ABSTRACT FROM AUTHOR]

Background: Drug-eluting stent has been shown to reduce the risk of repeated revascularization. However, as shown for first-generation drug-eluting stent, they may be counterbalanced by a potential higher risk of stent thrombosis, especially among ST-segment elevation myocardial infarction patients. In addition, diabetes has been shown to be an independent predictor of poor survival and repeated target vessel revascularization. No data have been reported so far on the long-term benefits and safety of new-generation drug-eluting stent in ST-segment elevation myocardial infarction according to diabetes. Therefore, the aim of this study was to evaluate whether diabetes may impact on the benefits from everolimus-eluting stent versus first-generation drug-eluting stent in patients undergoing primary angioplasty. Methods: We combined data from two randomized trials (PaclitAxel or Sirolimus-Eluting Stent vs Bare-Metal Stent in Primary Angioplasty and randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction) including consecutive ST-segment elevation myocardial infarction patients admitted within 12 h of symptom onset undergoing primary angioplasty and stent implantation at a tertiary centre with 24-h primary percutaneous coronary intervention capability. Primary endpoint of this study was major adverse cardiac events at 3-year follow-up. Secondary endpoints were as follows: (1) death, (2) reinfarction, (3) definite or probable ST and (4) target vessel revascularization at 3-year follow-up. No patient was lost to follow-up. Results: Our population is represented by 680 ST-segment elevation myocardial infarction patients treated with drug-eluting stent (180 enrolled in the PaclitAxel or Sirolimus-Eluting Stent vs Bare-Metal Stent in Primary Angioplasty trial, treated with first-generation drug-eluting stent, and 500 patients in the randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction, randomized to everolimus-eluting stent or sirolimus-eluting stent). Diabetes was observed in a total of 178 patients (26.1%) and associated with higher major adverse cardiac events, mortality, reinfarction, stent thrombosis and target vessel revascularization. Similar outcome was observed in terms of overall major adverse cardiac events, mortality, recurrent myocardial infarction, target vessel revascularization, with everolimus-eluting stent as compared to first-generation drug-eluting stent in both diabetic and non-diabetic patients, whereas everolimus-eluting stent was associated with a significantly lower rate of stent thrombosis only in diabetic patients (1.6% vs 9.6%, hazard ratio (95% confidence interval) = 0.15 (0.02−0.98), p = 0.04) whereas no difference was observed in non-diabetic patients. Conclusion: This study shows that among ST-segment elevation myocardial infarction patients undergoing primary angioplasty, diabetes is associated with a significantly worse outcome at 3-year follow-up. A similar outcome was observed between everolimus-eluting stent and first-generation drug-eluting stent in non-diabetic patients, whereas among diabetic patients everolimus-eluting stent was associated with a significant reduction in stent thrombosis. [ABSTRACT FROM AUTHOR]

Objectives: Although blood pressure is considered the major determinant of left ventricular hypertrophy in hypertension, genetic variability is increasingly being considered among the factors influencing this complication. β2-Adrenergic receptors (β2ARs) are up-regulated in hypertension and largely polymorphic within the human population. Recently, we have shown that the Glu27 β2AR variant is strongly associated with cardiac hypertrophy in hypertension. The objective of this study is to verify whether this polymorphism also affects hypertrophy regression in response to antihypertensive therapy.Methods: In a prospective follow-up study we screened 970 hypertensive patients of Caucasian descent for the Gly16Arg, Gln27Glu, and Thr164Ile β2AR polymorphisms and left ventricular echocardiographic hypertrophy and assigned selected patients to enalapril or atenolol to assess left ventricular hypertrophy regression after 2-year follow-up. Results were stratified according to treatment and the Glu27Gln polymorphism of the β2AR. In cells with stable overexpression of the Glu27 or Gln27 variant of β2AR, we also explored the implications of this polymorphism on hypertrophy-related intracellular signal transduction.Results: Among hypertensive patients, the Gly16 allele was found in 63% of patients and the Glu27 allele was found in 40.6%. Both polymorphisms were in linkage disequilibrium, as expected. Four hundred forty-one hypertrophic hypertensive patients completed the 2-year follow-up. At baseline, patients carrying at least 1 allele of the Glu27 variant presented with a larger cardiac size despite similar blood pressure levels (142.9 ± 22.5 g/m2 in Glu27 carriers versus 138.2 ± 18.4 g/m2 in Gln27 carriers, P < .02). Blood pressure normalization was achieved by both drugs. At follow-up, compared with the Gln27 patients, the Glu27 patients showed a larger reduction in hypertrophy when treated with enalapril (percent change in left ventricular mass, −6.3% ± 7.7% in Glu27 carriers versus −2.18% ± 7.9% in Gln27 carriers; P < .05) but not with atenolol therapy (−2.8% ± 8.9% in Glu27 carriers versus −2.4% ± 8.8% in Gln27 carriers, P = not significant). In in vitro studies the activation of p38 and extracellular signal-regulated kinase (ERK-) 1/2 (data not shown) and the activity of the atrial natriuretic factor (ANF) promoter after isoproterenol (INN, isoprenaline) stimulation were larger in Glu27 β2AR overexpressing cells than in Gln27 β2AR overexpressing cells (fold difference compared with unstimulated cells, 9.7 ± 2.9 for Glu27 β2AR versus 4.2 ± 0.3 for Gln27 β2AR; P < .05).Conclusions: The Glu27 variant of β2AR enhances hypertension-induced left ventricular hypertrophy. In these patients angiotensin-converting enzyme inhibitors are more efficient than β-blockers in reducing cardiac size.Clinical Pharmacology & Therapeutics (2006) 80, 633–645; doi: 10.1016/j.clpt.2006.09.006 [ABSTRACT FROM AUTHOR]